What if NNVC were to barrel through $1.41/sh in spectacular fashion? Just a "what if". After all, we never know exactly what next Monday "good news" will bring. People are beginning to understand better the science/bio-nanotechnology behind Nanoviricides, Inc.. It is like learning a new language. The sooner everyone understands it, learns it, the better we can communicate. Therefore, once we become experts like Dr. Seymour (see video signature) contact all friends, neighbors, family,...they will thank you for it.
Per the BigKahuna...Nanoviricides are currently binary: they either work in humans as they have in animals, or they don't. IMO, there is nothing in between. If they work in humans, then $10 billion will be leaving $40 billion on the table. Pharmassette went for $11 billion with one drug completing Phase 2 and ready for Phase 3. Do the math with that and 5 antiviral drugs plus 200 more in development.
Met with Dr. Seymour over lunch:
Some bullet points of things we discussed, none of which was not already public discussion from the company and officers:
-New site construction is ahead of schedule and should finish at the least on time. (This meeting was early Monday before this info was confirmed by NNVCbob onsite observations).
-Wants to move Dengue and flu simultaneously and has the money to do it.
-Because Dengue can't be tested through a challenge protocol with patients inoculated with the virus (made sick with Dengue then treated), it may be approved with only small phase 1/2a under orphan drug/breakthrough.
-In the coming months he will be reporting progress for EKC, HSV, HIV studies and general nanoviricide tweaking.
-IMO, the biggest thing, Anil was able to develop the MERS solution in less than a week. Less than a week for the type that will be tested in EU is pretty amazing and beats the 3 weeks of the rapid in field technology they previously talked about.
-Looking for an Aspire type deal for future money needs.
-Now looking to go it alone by a strategy of contract manufacturing and alternative avenues of distribution. At this point, he sees no reason to hand over a nanoviricide license after Anil and crew have done all the work, and that license in return for the smallest percentage. (I think this could change with the right deal, a partnership with 50/50 split and the partner picks up the remaining costs plus pays huge benchmarks. Those deals are out there.)
Some of the known Catalysts are:
Approval for DengueCide® orphan status ~ 3Q 2013
Well over 100 countries to approve "first in class" patent applications ~ 4Q 2013
Milestones -
-cGMP/R&D Center Shelton CT integration completes ~ 4Q 2013
-Commision new cGMP plant ~ 4Q 2013 (equipment moved in/3 identical test batches)
-Receive initial results toxicology studies FluCide ~ 4Q 2013
-Prepare IND for submission to regulatory authorities ~ 4Q 2013
Excerpt from 2009 Jain Report: Structure and function of nanoviricides
Advantages of NanoViricides
NanoViricides have been compared to current approaches to viral diseases, which are seldom curative and some of the advantages include the following:
§ Specific targeting of the virus with no metabolic adverse effects on the host.
§ The biological efficacy of NanoViricides drugs may be several orders of magnitude better than that of of usual chemical drugs. This in itself may limit the potential for mutant generation.
§ There are also other key aspects of the design of NanoViricides that are expected to lead to minimizing mutant generation.
§ Nanoviricides are safe because of their unique design and the fact that they are designed to be biodegradable within the body.
§ The new technology enables rapid drug development against an emerging virus, which would be important for global bio-security against natural as well as man-made (bio-terrorism) situations. It is possible to develop a research drug against a novel life-threatening viral disease within 3-6 weeks after the infection is found, i.e. as soon as an antibody from any animal source is available.
§ It is possible to make a single NanoViricide drug that responds to a large number of viral threats by using targeting ligands against the desired set of viruses in the construction of the drug.It is possible to “tune” the specificity and range (spectrum) of a NanoViricide drug within a virus type, subtype, or strain, by appropriate choices of the targeting ligand(s).
§ The safety of NanoViricide drugs is proven now as they specifically attack the virus and not the host.
§ A variety of formulations, release profiles and routes of administration are possible.
§ Low cost of drug development, manufacture, distribution.
NanoViricide drug candidates are currently in preclinical studies. Clinical trials are planned. Initially injectable products are considered to be most effective but alternative routes of administrations such as nasal sprays and bronchial aerosols can also be developed. Various Nanoviricide products will be described further along with relevant viral diseases.
Advantages of Nanoviricides over vaccines are
§ Nanoviricides work where vaccines fail and are effective even when the immune system is impaired such as in AIDS.
§ Nanoviricides work where effective vaccines are unavailable
§ Sufficient short term protection for an individual outbreak cluster-
§ Treatment can be started after infection
§ No need to vaccinate whole world population for control of a viral epidemic
AI
